Home › Research › Treatments
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study
Jamie L Fleet, Eric McArthur, Aakil Patel, Matthew A Weir, Manuel Montero-Odasso, Amit X Garg. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2019-09-16
Topic: Drug trials: efficacy and safety
Plain-language summary
The average age in our 2 groups was 81.1 years, and 61.4% of our population was female. Donepezil was associated with a higher risk of hospital admission with rhabdomyolysis compared with rivastigmine or galantamine (88 events in 152 300 patients [0.06%] v. 16 events in 68 053 patients [0.02%]; weighted odds ratio of 2.21, 95% confidence interval [CI] 1.52-3.22). Most hospital admissions with rhabdomyolysis after donepezil use were not severe, and no patient was treated with acute dialysis or mechanical ventilation. Initiating donepezil is associated with a higher 30-day risk of admission to hospital with rhabdomyolysis compared with initiating rivastigmine or galantamine. The proportion of patients who develop severe rhabdomyolysis within 30 days of initiating donepezil is very low.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fleet, J. L., McArthur, E., Patel, A., Weir, M. A., Montero-Odasso, M., & Garg, A. X. (2019). Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. https://doi.org/10.1503/cmaj.190337
Vancouver
Fleet JL, McArthur E, Patel A, Weir MA, Montero-Odasso M, Garg AX. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2019. doi:10.1503/cmaj.190337. PMID: 31527187.
BibTeX
@article{fleet2019-31527187,
author = {Fleet, Jamie L and McArthur, Eric and Patel, Aakil and Weir, Matthew A and Montero-Odasso, Manuel and Garg, Amit X},
title = {{Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study}},
journal = {CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne},
year = {2019},
doi = {10.1503/cmaj.190337},
pmid = {31527187},
url = {https://doi.org/10.1503/cmaj.190337}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The average age in our 2 groups was 81.1 years, and 61.4% of our population was female.
- Donepezil was associated with a higher risk of hospital admission with rhabdomyolysis compared with rivastigmine or galantamine (88 events in 152 300 patients [0.06%] v. 16 events in 68 053 patients [0.02%]; weighted odds ratio of 2.21, 95% confidence interval [CI] 1.52-3.22).
- Most hospital admissions with rhabdomyolysis after donepezil use were not severe, and no patient was treated with acute dialysis or mechanical ventilation.
- Initiating donepezil is associated with a higher 30-day risk of admission to hospital with rhabdomyolysis compared with initiating rivastigmine or galantamine.
- The proportion of patients who develop severe rhabdomyolysis within 30 days of initiating donepezil is very low.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Participants300
- Effect size61.4%; 0.06%; 0.02%
- Evidence strengthModerate
How this study scored 68/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 38 of the 56 points we could judge it on, which is 68 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 300 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31527187) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 38 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 38 of the 56 points we could judge it on is 68 out of 100. |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “cholinesterase”
271 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 271 tagged studies.